# US 2023/0069804 A1 · Methods and compositions for modulating splicing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069804 A1
- Document ID: US20230069804A1
- Status: Published application
- Kind: A1
- Application number: 17/391,361
- Filed: 2021-08-02
- Published: 2023-03-02
- Earliest claimed: 2019-02-04
- Assignees: Skyhawk Therapeutics, Inc.
- Applicants: SkyHawk Therapeutics, Inc.
- Inventors: Michael Luzzio; Brian Lucas; Tiansheng Wang
- Web page: https://patentgrep.com/patent/US20230069804A1

## CPC

- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 451/06: Oxygen atoms
- A61P 35/00: Antineoplastic agents
- C07D 417/14: containing three or more hetero rings
- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C07D 453/06: containing isoquinuclidine ring systems
- C07D 471/08: Bridged systems
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

## Claims

### Claim at position 1

1-108. (canceled)

### Claim 109

A compound of Formula (III), or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof:
wherein,
A is —O—, —S—, or —N(RN)—;
E is —NR—, —O—, —S—, —S(═O)—, —S(═O)2—, or —S(═O)(═NRE)—;
RE is hydrogen, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C5 heterocycloalkyl, substituted or unsubstituted C2-C3 alkenyl, or substituted or unsubstituted C2-C3 alkynyl;
RN is hydrogen, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C5 heterocycloalkyl, substituted or unsubstituted C2-C3 alkenyl, or substituted or unsubstituted C2-C3 alkynyl;
ring Q is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
is a single bond or a double bond;
X is
and Z is C; or
X is —O—, —S—, —NR3—,
and Z is CR2;
W is substituted or unsubstituted C1-C3 alkylene, substituted or unsubstituted C2-C3 alkenylene, substituted or unsubstituted C1-C2 heteroalkylene, substituted or unsubstituted C3-C8 cycloalkylene, or substituted or unsubstituted C2-C7 heterocycloalkylene;
R is hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 fluoroalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted or unsubstituted C2-C5 heterocycloalkyl;
each R1 is independently hydrogen, deuterium, substituted or unsubstituted C1-C4 alkyl, —CD3, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C5 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is hydrogen, deuterium, substituted or unsubstituted C1-C4 alkyl, —CD3, or substituted or unsubstituted C1-C4 haloalkyl;
R3 is hydrogen, —CN, substituted or unsubstituted C1-C4 alkyl, —CD3, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 heteroalkyl, —C1-C4 alkylene-OR1, substituted or unsubstituted C3-C4 cycloalkyl, or substituted or unsubstituted C2-C3 heterocycloalkyl;
each R4 is independently hydrogen, deuterium, substituted or unsubstituted C1-C4 alkyl, —CD3, substituted or unsubstituted C1-C4 haloalkyl, or substituted or unsubstituted C1-C4 heteroalkyl;
each R11, R12, R13, R14, R16, and R17 is independently selected from the group consisting of hydrogen, deuterium, F, —OR1, substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C1-C4 fluoroalkyl, and substituted or unsubstituted C1-C4 heteroalkyl;
R15 and R18 are independently selected from the group consisting of hydrogen, deuterium, F, —OR1, substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C1-C4 fluoroalkyl, and substituted or unsubstituted C1-C4 heteroalkyl;
a is 0, b is 0, c is 1, and d is 1; or
a is 1, b is 0, c is 1, and d is 0.

### Claim 110 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein the compound has a structure of Formula (I):
wherein,
X is —O—, —S—, or —NR3—, and Z is CR2;
E is —NR—, —O—, —S—, —S(═O)—, —S(═O)2—, or —S(═O)(═NRE)—; and
R is hydrogen.

### Claim 111 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein the compound has a structure of Formula (II):
wherein,
X is —O—, —S—, or —NR3—, and Z is CR2; and
R is substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 fluoroalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted or unsubstituted C2-C5 heterocycloalkyl.

### Claim 112 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein the compound has a structure of Formula (I):
wherein,
X is
Z is CR2; and
R is hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 fluoroalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted or unsubstituted C2-C5 heterocycloalkyl.

### Claim 113 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein
X is
and Z is C; or
X is
and Z is CR2;
R is hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 fluoroalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, or substituted or unsubstituted C2-C5 heterocycloalkyl.

### Claim 114 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring Q is 2-hydroxy-phenyl substituted with substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

### Claim 115 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring Q is 2-hydroxy-phenyl substituted with substituted or unsubstituted heteroaryl, wherein if heteroaryl is substituted then it is substituted with 1 or 2 substituents independently selected from:
deuterium, halogen, —OH, —NO2, oxo, —CN, —SR1, —S(═O)R1, —S(═O)2R1, —N(R1)2, —C(═O)R1, —OC(═O)R1, —C(═O)OR1, —C(═O)N(R1)2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C7 cycloalkyl, and substituted or unsubstituted C2-C7 heterocycloalkyl; wherein
each R1 is independently hydrogen, deuterium, substituted or unsubstituted C1-C4 alkyl, —CD3, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C5 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 116 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein:
ring Q is
wherein each RQ is independently selected from hydrogen, deuterium, —F, —Cl, —CN, —OH, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CF3, —OCH3, —OCH2CH3, —CH2OCH3, —OCH2CH2CH3, and —OCH(CH3)2; and ring P is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

### Claim 117 (depends on 116)

The compound of claim 116, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring P is substituted or unsubstituted heteroaryl.

### Claim 118 (depends on 116)

The compound of claim 116, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring P is heteroaryl selected from the group consisting of:
wherein,
each RB is independently selected from hydrogen, deuterium, halogen, hydroxy, cyano, substituted or unsubstituted C1-C6 alkyl, —CD3, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, deuterium substituted C1-C6 alkoxy, —OCD3, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
RB1 is selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, —CD3, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C3-7 cycloalkyl, and substituted or unsubstituted C2-C7 heterocycloalkyl; and
m is 2 or 3.

### Claim 119 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring Q is substituted or unsubstituted heteroaryl; wherein if heteroaryl is substituted, then it is substituted with one or more substituents each independently selected from D, halogen, —CN, —NH2, —OH, ═O, —NH(CH3), —N(CH3)2, —NH(cyclopropyl), —CH3, —CH2CH3, —CF3, —OCH3, and —OCF3.

### Claim 120 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein ring Q is selected from the group consisting of:
wherein ring Q is optionally substituted with 1, 2, 3, 4, or 5 RB, wherein each RB is independently selected from deuterium, halogen, hydroxy, cyano, substituted or unsubstituted C1-C6 alkyl, —CD3, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, deuterium substituted C1-C6 alkoxy, —OCD3, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
or wherein ring Q is selected from the group consisting of:
wherein
RB1 is selected from hydrogen, deuterium, substituted or unsubstituted C1-C6 alkyl, —CD3, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C3-7 cycloalkyl, and substituted or unsubstituted C2-C7 heterocycloalkyl.

### Claim 121 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein W is substituted or unsubstituted C1-C3 alkylene or substituted or unsubstituted C1-C2 heteroalkylene.

### Claim 122 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein W is —CH2OCH2—, —CH2CH2— or —CH2CH2CH2—.

### Claim 123 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein R2 is hydrogen.

### Claim 124 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein R16 is F and R17 is hydrogen; or wherein R16 is hydrogen and R17 is F.

### Claim 125 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein X is —NR3— and R3 is hydrogen, —CH3, —CH2CH3, —CH(CH3)2, —CH2F, —CHF2, or —CF3.

### Claim 126 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein X is —O— or —S—.

### Claim 127 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein R15 is hydrogen or —CH3, and R18 is hydrogen or —CH3.

### Claim 128 (depends on 109)

The compound of claim 109, or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein at least one of R11, R12, R13, R14, R15, R16, R17, and R18 is or comprises a fluorine.
